Top

Published in:

Open Access 01-04-2021 | Breast Cancer | Original Article

CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario

Authors: Satish Sankaran, Jyoti Bajpai Dikshit, Chandra Prakash SV, SE Mallikarjuna, SP Somashekhar, Shekhar Patil, Rajeev Kumar, Krishna Prasad, Dinesh Shet, Manjiri M. Bakre

Published in: Indian Journal of Surgical Oncology | Special Issue 1/2021

Abstract

CanAssist Breast (CAB) has thus far been validated on a retrospective cohort of 1123 patients who are mostly Indians. Distant metastasis–free survival (DMFS) of more than 95% was observed with significant separation (P < 0.0001) between low-risk and high-risk groups. In this study, we demonstrate the usefulness of CAB in guiding physicians to assess risk of cancer recurrence and to make informed treatment decisions for patients. Of more than 500 patients who have undergone CAB test, detailed analysis of 455 patients who were treated based on CAB-based risk predictions by more than 140 doctors across India is presented here. Majority of patients tested had node negative, T2, and grade 2 disease. Age and luminal subtypes did not affect the performance of CAB. On comparison with Adjuvant! Online (AOL), CAB categorized twice the number of patients into low risk indicating potential of overtreatment by AOL-based risk categorization. We assessed the impact of CAB testing on treatment decisions for 254 patients and observed that 92% low-risk patients were not given chemotherapy. Overall, we observed that 88% patients were either given or not given chemotherapy based on whether they were stratified as high risk or low risk for distant recurrence respectively. Based on these results, we conclude that CAB has been accepted by physicians to make treatment planning and provides a cost-effective alternative to other similar multigene prognostic tests currently available.

Dhillon PK, Mathur P, Nandakumar A et al (2018) The burden of cancers and their variations across the states of India: the global burden of disease. Lancet Oncol 19:1289–1306CrossRef

Malvia S, Appalaraju B, Uma S et al (2017) Epidemiology of breast cancer in Indian women. Asia-Pacific J Clin Oncol 13:289–295CrossRef

Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML et al (2010) The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Pub Health 21(5):573–577CrossRef

Sharma R (2019) Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: evidence from Global Burden of Disease Study 2016. Breast Cancer doi.org/10.1007/s12282-018-00941-4

Wickerham LD, O’Conell MJ, Costantino JP et al (2008) The half century of clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Seminal Oncol 35(5):522–529CrossRef

Schmidt M (2014) Chemotherapy in early breast cancer: when, how and which one? Breast Care 9:154–160CrossRef

Furquhar C, Majoribanks J, A Lethaby A et al (2016) High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database of Systematic Reviews DOI: https://doi.org/10.1002/14651858.CD003139.pub3

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121CrossRef

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRef

10.

Van De Vijver MJ, He YD, Van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl J Med 347(25): 1999–2009

11.

Nielsen TO, Parker JS, Leung S et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer. Clin Cancer Res 16(21):5222–5232

12.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M, EP Investigators (2011) A new molecular predictor of distant recurrence in ER positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17(18):6012–6020CrossRef

13.

Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O (2011) Prognostic utility of HOXB13: IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104(11):1762–1769CrossRef

14.

Ramkumar C, Buturovic L, Malpani S et al (2018) Development of a novel proteomic risk-classifier for prognostication of patients with early-stage hormone receptor–positive breast cancer. Biomark Insights 13:1177271918789100CrossRef

15.

Bakre MM, Ramkumar C, Attuluri AK et al (2019) Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. Cancer Med doi. https://doi.org/10.1002/cam4.2049

16.

Attuluri AK, Prakash VSC, Gunda A et al (2019) Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients. BMC Cancer 19(1):249CrossRef

17.

Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen’s International Expert consensus on the primary therapy of early breast cancer 2013. Annals Oncol 24:2206–2223CrossRef

18.

Cardoso F, van’t Veer LJ, Bogearts J et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. New Eng J Med 25;375(8):717-29

19.

Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD (2010) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12(1):R1CrossRef

20.

Haybittle JL, Blamey RW, Elston CW et al., A prognostic index in primary breast cancer. (1982) Br J Cancer 45(3):361–366

21.

Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991CrossRef

22.

Raina V, Bhutani M, Bedi R et al (2005) Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Ind J Cancer 42(1): 36-41. Int Surg J 4(3): 913–915

23.

Agarwal G, Ramakant P (2008) Breast cancer care in India: current scenario and challenges for the future. Breast Care 3:21–27CrossRef

24.

Almas A (2017) Clinical profile of carcinoma breast cases at a tertiary care hospital. Int J Surg 4(3):913–915CrossRef

25.

Lambertini M, Pinto AC, Ameye L et al (2016) The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. British J of Cancer 115:1471–1478CrossRef

26.

Engelhardt EG, Garvelink MM, de Haes JH et al (2014) Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol 20 32(3):238–250CrossRef

27.

Maishman T, Copson E, Stanton L, Gerty S, Dicks E, Durcan L et al. (2015) An evaluation of the prognostic model PREDICT using the POSH cohort of women aged 40 years at breast cancer diagnosis. Br J Cancer112(6):983-991

28.

Sivasubramaniam PG, Zhang B, Zhang Q et al (2015) Breast cancer disparities: a multicenter comparison of tumor diagnosis, characteristics, and surgical treatment in China and the U.S. The Oncol 20:1044–1050CrossRef

29.

Kwang A, Cheung P, Chan S et al (2008) Breast cancer in Chinese women younger than age 40: are they different from their solder counterparts? World J Surg 32(12):2554–2561CrossRef

30.

Lo SS, Mumby PB, Norton J et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection 10:1671-1676

31.

Curtit E, Vanettzel J, Darmon J et al (2019) Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: real-life utilization and decision impact in French clinical practice. BMC Cancer:39–45

32.

Holt S, Bartelli G, Humphreys I et al (2013) A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK B J Cancer 108, 2250–2258

33.

Müller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S, Schoenegg W, Eucker J, Schmidt M, Lippek F, Jöhrens K, Pahl S, Sinn BV, Budczies J, Dietel M, Denkert C (2013) The EndoPredict gene-expression assay in clinical practice - performance and impact on clinical decisions. PLoS One 8(6):e68252CrossRef

34.

Kuijer A, Straver M, Dekker B et al (2017) Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor–positive early breast cancer: results of a prospective cohort study. J Clin Oncol 24:2814–2819CrossRef

Title: CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario
Authors: Satish Sankaran
Jyoti Bajpai Dikshit
Chandra Prakash SV
SE Mallikarjuna
SP Somashekhar
Shekhar Patil
Rajeev Kumar
Krishna Prasad
Dinesh Shet
Manjiri M. Bakre
Publication date: 01-04-2021
Publisher: Springer India
Keywords: Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Indian Journal of Surgical Oncology / Issue Special Issue 1/2021
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-019-01014-4

At a glance: The STEP trials

Springer Medicine

CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2021

Molecular Oncology in Management of Colorectal Cancer

mRNA Expression Analysis of E-Cadherin, VEGF, and MMPs in Gastric Cancer: a Pilot Study

Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine

GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma

Genetic Counseling Clinic at AIIMS (New Delhi)

TRF2 Overexpression at the Surgical Resection Margin: A Potential Predictive Biomarker in Oral Squamous Cell Carcinoma for Recurrence